In this study, the integration of proteomics, metabolomics, and lipidomics data from PCa patients facilitated the identification of four analytes (tenascin C (TNC), apolipoprotein A-IV (APOA-IV), 1-methyladenosine, and phosphatidic acid 18:0–22:0) as potential biomarkers to discriminate BCR from non-BCR patients. This evidence concerns the gene APOA4 and posterior cortical atrophy.